Myriad Genetics is focused on the future. Our current test portfolio is centered on molecular diagnostic tests for Oncology, Women’s Health, Dermatology and Urology. Additionally, we are developing tests for Autoimmune, and Neuroscience diseases.
Our molecular diagnostic product pipeline is strong and includes 13 tests across multiple medical specialties as well as companion diagnostics.
With a focus on the future, our current tests and pipeline products all were developed with an effort to solve the core issues currently facing the healthcare system including:
- Rising Costs
- Ineffective Treatments
- Unnecessary Treatments
- Fragmented Decision Making
By developing tests for pressing clinical needs Myriad’s solutions are targeted at disease prevention, early diagnosis, and the optimal treatment for the patient. Just one more way that Myriad is empowering people to own their healthcare.